Cellectis Presents Preclinical APOC3 Gene-Editing Data at ESGCT 2026
Cellectis presented preclinical data showing effective APOC3 gene editing and a marked reduction in triglycerides with.HEAL-101.
Related stories
OMV Petrom Publishes Q3 2026 Results Presentation Transcript
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Luxshare Precision Reports Q3 Revenue Up 14.6% Year Over Year
Luxshare Precision said third-quarter revenue rose 14.6% year over year.
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Luxshare Precision Says Q3 Revenue Rose 14.6% YoY
Luxshare Precision said third-quarter revenue increased 14.6% year over year.
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Luxshare Precision Says Q3 Net Profit Rose 7% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
Bankwell Reports Higher Q3 2026 Net Income and Revenue
Bankwell reported year-over-year increases in Q3 2026 net income and revenue.
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC
First Mid Bancshares to Acquire Evergreen Bancshares for $70.7 Million
First Mid Bancshares will acquire Evergreen Bancshares for $70.7 million.
M impact | EQUITY | Oct 29, 2026, 12:25 PM UTC